Merck

We’re presenting new data at #ASCO26 from our robust oncology portfolio and pipeline across earlier-stage and advanced tumor types. We’re focused on advancing research to fight cancer and evaluate new approaches to help prolong and protect lives. Learn more: go.merck.com/~k8y

Today, we announced the first positive Phase 3 results from our investigational TROP2-directed antibody-drug conjugate (ADC) in certain patients with advanced or recurrent endometrial cancer. This milestone represents the first results from our broad TroFuse clinical trial program and reflects our ongoing commitment to advancing research in women’s cancers. Learn more here: go.merck.com/~5pc

Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in @ScienceMagazine, we share how we’re using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more: go.merck.com/~4hh

Today, Merck completed the acquisition of Terns Pharmaceuticals, further strengthening our #oncology portfolio and reinforcing our focus on science‑driven innovation. Learn more: go.merck.com/~3wh

Join us today at 9 a.m. ET to learn more about our Q1 2026 #earnings: go.merck.com/~cn3 $MRK

Our Q1 2026 #earnings results are live. Check out our full $MRK financial summary and key highlights: go.merck.com/~e42

Now that baseball season has returned to ballparks across the country, we’re proud to team up with @WomenHeartOrg & 9 professional baseball teams to help shine a spotlight on bad cholesterol & the risk of heart attack or stroke. Learn more about Playing with Heart: go.merck.com/~ovx

We’re proud to partner with @googlecloud to help shape the future of biopharmaceutical innovation with AI-enabled enterprise transformation. This collaboration is about unlocking new value: accelerating discovery, modernizing how we work and empowering our teams to focus on the highest-impact science and solutions for patients. Learn more about the landmark partnership: go.merck.com/~xz9

There’s a new treatment option for certain adults living with HIV. Learn more here: go.merck.com/~ux0

Learn more about our latest update in #oncology: go.merck.com/~wy2

The FDA accepted our application for a perioperative treatment for #BladderCancer, which affects 84,000+ people in the U.S. each year. With @pfizer and @AstellasUS , we’re committed to advancing care and addressing recurrence in muscle-invasive disease. Learn more: go.merck.com/~wtd

Today, we’re proud to announce the European Commission’s approval of an option to help protect infants against respiratory syncytial virus (#RSV). Learn more: go.merck.com/~3mw

@karriehiggins Hi, we're sorry to hear your frustration. Please contact our National Service Center at dpoc.usa@merck.com or 1.800.672.6372 and they can do their best to address your concern.

Since 11/24, I have been trying to get approval for the @Merck cares program for a medication that I cannot get covered. The coupon is a joke. I need assistance. I would really like to SLEEP esp. since I have epilepsy, but they send me forms, I fill them out ...

Today, in collaboration with @DaiichiSankyoUS, we are proud to announce that the #FDA has granted Priority Review for a new treatment option for certain patients with extensive-stage small cell lung #cancer. Learn more here: go.merck.com/~09i

Today we announced the initiation of a pivotal Phase 2b/3 trial for the treatment of patients with neovascular age-related macular degeneration (#wetAMD). Learn more: go.merck.com/~3u5 #ophthalmology

The European Commission has approved a new treatment option for certain patients with platinum-resistant recurrent #OvarianCancer — a community that has faced a significant unmet treatment need. Learn more: go.merck.com/~437

Today at #ACC26, we’re sharing Phase 3 results of our investigational oral macrocyclic peptide. Learn more: go.merck.com/~abm

We’re sharing data for our Phase 2 study in an uncommon type of pulmonary hypertension at #ACC26. Read more: go.merck.com/~11g

Today, we announced an agreement to acquire @TernsPharma, adding a potential best-in-class candidate for the treatment of certain patients with chronic myeloid #leukemia (#CML) to our growing #hematology pipeline: go.merck.com/~ufj1s8